{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:06:22Z","timestamp":1792724782601,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"8007","license":[{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2024,4,11]]},"DOI":"10.1038\/s41586-024-07233-2","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T13:03:24Z","timestamp":1711544604000},"page":"416-423","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["TRBC1-targeting antibody\u2013drug conjugates for the treatment of T cell cancers"],"prefix":"10.1038","volume":"628","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4091-7580","authenticated-orcid":false,"given":"Tushar D.","family":"Nichakawade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9152-6267","authenticated-orcid":false,"given":"Jiaxin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9988-7147","authenticated-orcid":false,"given":"Brian J.","family":"Mog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bum Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3504-7517","authenticated-orcid":false,"given":"Alexander H.","family":"Pearlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah R.","family":"DiNapoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Wyhs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0232-081X","authenticated-orcid":false,"given":"Nikita","family":"Marcou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Glavaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5045-5255","authenticated-orcid":false,"given":"Maximilian F.","family":"Konig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1205-5204","authenticated-orcid":false,"given":"Sandra B.","family":"Gabelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangeline","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cole","family":"Sterling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Wagner-Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Rozati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lode","family":"Swinnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephraim","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6215-1013","authenticated-orcid":false,"given":"Drew M.","family":"Pardoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Gabrielson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7135-7451","authenticated-orcid":false,"given":"Nickolas","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9991-7123","authenticated-orcid":false,"given":"Chetan","family":"Bettegowda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Kinzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1941-4425","authenticated-orcid":false,"given":"Shibin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surojit","family":"Sur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0766-3854","authenticated-orcid":false,"given":"Bert","family":"Vogelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9357-3702","authenticated-orcid":false,"given":"Suman","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,27]]},"reference":[{"key":"7233_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64\u201373 (2018).","journal-title":"N. Engl. J. Med."},{"key":"7233_CR2","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651\u2013668 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"7233_CR3","doi-asserted-by":"publisher","unstructured":"Zahavi, D. & Weiner, L. Monoclonal antibodies in cancer therapy. Antibodies https:\/\/doi.org\/10.3390\/antib9030034 (2020).","DOI":"10.3390\/antib9030034"},{"key":"7233_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu, Z., Li, S., Han, S., Shi, C. & Zhang, Y. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduct. Target. Ther. 7, 93 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"7233_CR5","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner, R. G. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603, 934\u2013941 (2022).","journal-title":"Nature"},{"key":"7233_CR6","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMe2118899","volume":"386","author":"M Roschewski","year":"2022","unstructured":"Roschewski, M., Longo, D. L. & Wilson, W. H. CAR T-cell therapy for large B-cell lymphoma\u2014who, when, and how? N. Engl. J. Med. 386, 692\u2013696 (2022).","journal-title":"N. Engl. J. Med."},{"key":"7233_CR7","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo, F. et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N. Engl. J. Med. 388, 1284\u20131295 (2023).","journal-title":"N. Engl. J. Med."},{"key":"7233_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","volume":"18","author":"L Mikkilineni","year":"2021","unstructured":"Mikkilineni, L. & Kochenderfer, J. N. CAR T cell therapies for patients with multiple myeloma. Nat. Rev. Clin. Oncol. 18, 71\u201384 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"7233_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/d41573-022-00040-2","volume":"21","author":"A Esfandiari","year":"2022","unstructured":"Esfandiari, A., Cassidy, S. & Webster, R. M. Bispecific antibodies in oncology. Nat. Rev. Drug. Discov. 21, 411\u2013412 (2022).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"7233_CR10","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","volume":"109","author":"AK Fielding","year":"2007","unstructured":"Fielding, A. K. et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study. Blood 109, 944\u2013950 (2007).","journal-title":"Blood"},{"key":"7233_CR11","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3324\/haematol.2017.186577","volume":"103","author":"M Bellei","year":"2018","unstructured":"Bellei, M. et al. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. Haematologica 103, 1191\u20131197 (2018).","journal-title":"Haematologica"},{"key":"7233_CR12","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/nm.4444","volume":"23","author":"PM Maciocia","year":"2017","unstructured":"Maciocia, P. M. et al. Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies. Nat. Med. 23, 1416\u20131423 (2017).","journal-title":"Nat. Med."},{"key":"7233_CR13","doi-asserted-by":"crossref","unstructured":"Cwynarski, K. et al. First in Human Study of AUTO4, a TRBC1-Targeting CAR T-Cell Therapy in R\/R TRBC1-Positive Peripheral T Cell Lymphoma (Autolus Therapeutics, 2022); www.autolus.com\/media\/1zsbaddr\/4634-auto4-poster.pdf.","DOI":"10.1182\/blood-2022-165971"},{"key":"7233_CR14","doi-asserted-by":"publisher","first-page":"10316","DOI":"10.1182\/blood-2022-165971","volume":"140","author":"K Cwynarski","year":"2022","unstructured":"Cwynarski, K. et al. First in human study of AUTO4, a TRBC1-targeting CAR T-cell therapy in relapsed\/refractory TRBC1-positive peripheral T-cell lymphoma. Blood 140, 10316\u201310317 (2022).","journal-title":"Blood"},{"key":"7233_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"7233_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"7233_CR17","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","volume":"24","author":"P Went","year":"2006","unstructured":"Went, P. et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J. Clin. Oncol. 24, 2472\u20132479 (2006).","journal-title":"J. Clin. Oncol."},{"key":"7233_CR18","doi-asserted-by":"publisher","first-page":"308ra158","DOI":"10.1126\/scitranslmed.aaa9122","volume":"7","author":"IR Kirsch","year":"2015","unstructured":"Kirsch, I. R. et al. TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. Sci. Transl. Med. 7, 308ra158 (2015).","journal-title":"Sci. Transl. Med."},{"key":"7233_CR19","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1182\/blood-2002-08-2438","volume":"101","author":"V Asnafi","year":"2003","unstructured":"Asnafi, V. et al. Analysis of TCR, pT\u03b1, and RAG-1 in T-acute lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment. Blood 101, 2693\u20132703 (2003).","journal-title":"Blood"},{"key":"7233_CR20","doi-asserted-by":"publisher","first-page":"4173","DOI":"10.1182\/blood-2003-11-3944","volume":"104","author":"V Asnafi","year":"2004","unstructured":"Asnafi, V. et al. Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy. Blood 104, 4173\u20134180 (2004).","journal-title":"Blood"},{"key":"7233_CR21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/312541a0","volume":"312","author":"JE Sims","year":"1984","unstructured":"Sims, J. E., Tunnacliffe, A., Smith, W. J. & Rabbitts, T. H. Complexity of human T-cell antigen receptor \u03b2-chain constant- and variable-region genes. Nature 312, 541\u2013545 (1984).","journal-title":"Nature"},{"key":"7233_CR22","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/hon.3163_44","volume":"41","author":"K Cwynarski","year":"2023","unstructured":"Cwynarski, K. et al. First in human study of AUTO4, a TRBC1-tragetting CAR T cell therapy in relapsed\/refractory TRBC1-positive peripheral T-cell lymphoma. Hematol. Oncol. 41, 80\u201381 (2023).","journal-title":"Hematol. Oncol."},{"key":"7233_CR23","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"7233_CR24","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero, P. et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N. Engl. J. Med. 388, 1002\u20131014 (2023).","journal-title":"N. Engl. J. Med."},{"key":"7233_CR25","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"7233_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry, T. J. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat. Med. 24, 20\u201328 (2018).","journal-title":"Nat. Med."},{"key":"7233_CR27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517\u2013528 (2015).","journal-title":"Lancet"},{"key":"7233_CR28","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1126\/science.314668","volume":"206","author":"P Kung","year":"1979","unstructured":"Kung, P., Goldstein, G., Reinherz, E. L. & Schlossman, S. F. Monoclonal antibodies defining distinctive human T cell surface antigens. Science 206, 347\u2013349 (1979).","journal-title":"Science"},{"key":"7233_CR29","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.4049\/jimmunol.124.6.2708","volume":"124","author":"JP Van Wauwe","year":"1980","unstructured":"Van Wauwe, J. P., De Mey, J. R. & Goossens, J. G. OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. J. Immunol. 124, 2708\u20132713 (1980).","journal-title":"J. Immunol."},{"key":"7233_CR30","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/eji.1830190920","volume":"19","author":"HJ Schlitt","year":"1989","unstructured":"Schlitt, H. J., Kurrle, R. & Wonigeit, K. T cell activation by monoclonal antibodies directed to different epitopes on the human T cell receptor\/CD3 complex: evidence for two different modes of activation. Eur. J. Immunol. 19, 1649\u20131655 (1989).","journal-title":"Eur. J. Immunol."},{"key":"7233_CR31","doi-asserted-by":"publisher","first-page":"5921","DOI":"10.4049\/jimmunol.159.12.5921","volume":"159","author":"BL Levine","year":"1997","unstructured":"Levine, B. L. et al. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J. Immunol. 159, 5921\u20135930 (1997).","journal-title":"J. Immunol."},{"key":"7233_CR32","doi-asserted-by":"publisher","first-page":"eabd3595","DOI":"10.1126\/scitranslmed.abd3595","volume":"13","author":"S Paul","year":"2021","unstructured":"Paul, S. et al. TCR \u03b2 chain-directed bispecific antibodies for the treatment of T cell cancers. Sci. Transl. Med. 13, eabd3595 (2021).","journal-title":"Sci. Transl. Med."},{"key":"7233_CR33","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41375-021-01385-0","volume":"36","author":"PA Wawrzyniecka","year":"2022","unstructured":"Wawrzyniecka, P. A., Ibrahim, L., Gritti, G., Pule, M. A. & Maciocia, P. M. Chimeric antigen receptor T cells for gamma-delta T cell malignancies. Leukemia 36, 577\u2013579 (2022).","journal-title":"Leukemia"},{"key":"7233_CR34","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581\u2013590 (2015).","journal-title":"Nat. Med."},{"key":"7233_CR35","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/mt.2016.63","volume":"24","author":"T Gargett","year":"2016","unstructured":"Gargett, T. et al. GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade. Mol. Ther. 24, 1135\u20131149 (2016).","journal-title":"Mol. Ther."},{"key":"7233_CR36","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1084\/jem.165.4.1141","volume":"165","author":"MS Krangel","year":"1987","unstructured":"Krangel, M. S. Endocytosis and recycling of the T3-T cell receptor complex. The role of T3 phosphorylation. J. Exp. Med. 165, 1141\u20131159 (1987).","journal-title":"J. Exp. Med."},{"key":"7233_CR37","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S1074-7613(00)00066-2","volume":"13","author":"H Liu","year":"2000","unstructured":"Liu, H., Rhodes, M., Wiest, D. L. & Vignali, D. A. On the dynamics of TCR:CD3 complex cell surface expression and downmodulation. Immunity 13, 665\u2013675 (2000).","journal-title":"Immunity"},{"key":"7233_CR38","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani, Y. et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin. Cancer Res. 22, 5097\u20135108 (2016).","journal-title":"Clin. Cancer Res."},{"key":"7233_CR39","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","volume":"102","author":"JA Francisco","year":"2003","unstructured":"Francisco, J. A. et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102, 1458\u20131465 (2003).","journal-title":"Blood"},{"key":"7233_CR40","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","volume":"131","author":"F Zammarchi","year":"2018","unstructured":"Zammarchi, F. et al. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood 131, 1094\u20131105 (2018).","journal-title":"Blood"},{"key":"7233_CR41","doi-asserted-by":"publisher","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","volume":"68","author":"GD Lewis Phillips","year":"2008","unstructured":"Lewis Phillips, G. D. et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 68, 9280\u20139290 (2008).","journal-title":"Cancer Res."},{"key":"7233_CR42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature07668","volume":"457","author":"A Xiao","year":"2009","unstructured":"Xiao, A. et al. WSTF regulates the H2A.X DNA damage response via a novel tyrosine kinase activity. Nature 457, 57\u201362 (2009).","journal-title":"Nature"},{"key":"7233_CR43","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.1074\/jbc.273.10.5858","volume":"273","author":"EP Rogakou","year":"1998","unstructured":"Rogakou, E. P., Pilch, D. R., Orr, A. H., Ivanova, V. S. & Bonner, W. M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 273, 5858\u20135868 (1998).","journal-title":"J. Biol. Chem."},{"key":"7233_CR44","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1309\/AJCP09OTJOYAVZZK","volume":"136","author":"AC Hristov","year":"2011","unstructured":"Hristov, A. C., Vonderheid, E. C. & Borowitz, M. J. Simplified flow cytometric assessment in mycosis fungoides and Sezary syndrome. Am. J. Clin. Pathol. 136, 944\u2013953 (2011).","journal-title":"Am. J. Clin. Pathol."},{"key":"7233_CR45","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1182\/blood-2003-07-2466","volume":"103","author":"JF DiJoseph","year":"2004","unstructured":"DiJoseph, J. F. et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 103, 1807\u20131814 (2004).","journal-title":"Blood"},{"key":"7233_CR46","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","volume":"379","author":"S Castaigne","year":"2012","unstructured":"Castaigne, S. et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 379, 1508\u20131516 (2012).","journal-title":"Lancet"},{"key":"7233_CR47","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","volume":"22","author":"PF Caimi","year":"2021","unstructured":"Caimi, P. F. et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 22, 790\u2013800 (2021).","journal-title":"Lancet Oncol."},{"key":"7233_CR48","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1182\/blood.2020007512","volume":"137","author":"M Hamadani","year":"2021","unstructured":"Hamadani, M. et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma. Blood 137, 2634\u20132645 (2021).","journal-title":"Blood"},{"key":"7233_CR49","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41586-018-0326-5","volume":"559","author":"TL Roth","year":"2018","unstructured":"Roth, T. L. et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature 559, 405\u2013409 (2018).","journal-title":"Nature"},{"key":"7233_CR50","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/S0161-5890(97)00144-2","volume":"34","author":"IC Nicholson","year":"1997","unstructured":"Nicholson, I. C. et al. Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. Mol. Immunol. 34, 1157\u20131165 (1997).","journal-title":"Mol. Immunol."},{"key":"7233_CR51","doi-asserted-by":"publisher","first-page":"ra45","DOI":"10.1126\/scisignal.2004882","volume":"7","author":"S Paul","year":"2014","unstructured":"Paul, S. et al. T cell receptor signals to NF-\u03baB are transmitted by a cytosolic p62-Bcl10-Malt1-IKK signalosome. Sci. Signal. 7, ra45 (2014).","journal-title":"Sci. Signal."},{"key":"7233_CR52","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.immuni.2012.04.008","volume":"36","author":"S Paul","year":"2012","unstructured":"Paul, S., Kashyap, A. K., Jia, W., He, Y. W. & Schaefer, B. C. Selective autophagy of the adaptor protein Bcl10 modulates T cell receptor activation of NF-\u03baB. Immunity 36, 947\u2013958 (2012).","journal-title":"Immunity"},{"key":"7233_CR53","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1039\/b922045c","volume":"135","author":"ZM Zhang","year":"2010","unstructured":"Zhang, Z. M., Chen, S. & Liang, Y. Z. Baseline correction using adaptive iteratively reweighted penalized least squares. Analyst 135, 1138\u20131146 (2010).","journal-title":"Analyst"},{"key":"7233_CR54","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1021\/acs.analchem.5b00140","volume":"87","author":"MT Marty","year":"2015","unstructured":"Marty, M. T. et al. Bayesian deconvolution of mass and ion mobility spectra: from binary interactions to polydisperse ensembles. Anal. Chem. 87, 4370\u20134376 (2015).","journal-title":"Anal. Chem."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-07233-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-07233-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-07233-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T12:06:20Z","timestamp":1716552380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-07233-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":54,"journal-issue":{"issue":"8007","published-print":{"date-parts":[[2024,4,11]]}},"alternative-id":["7233"],"URL":"https:\/\/doi.org\/10.1038\/s41586-024-07233-2","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,27]]},"assertion":[{"value":"19 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Johns Hopkins University has filed patent applications related to technologies described in this paper on which S.P., T.D.N., B.V., K.W.K., N.P. and S.Z. are listed as inventors. S.P. is a consultant to Merck, owns equity in Gilead and received payment from IQVIA and Curio Science. B.V., K.W.K. and N.P. are founders of Thrive Earlier Detection, an Exact Sciences Company. K.W.K. and N.P. are consultants to Thrive Earlier Detection. B.V., K.W.K., N.P. and S.Z. hold equity in Exact Sciences. B.V., K.W.K., N.P. and S.Z. are founders of or consultants to and own equity in ManaT Bio, Neophore and Personal Genome Diagnostics. B.V., K.W.K. and N.P. hold equity in Haystack Oncology and CAGE Pharma. N.P. is a consultant to Vidium. M.F.K. received personal fees from Argenx, Atara Biotherapeutics, Revel Pharmaceuticals, Sana Biotechnology, Sanofi and Doximity, all unrelated to this work. B.V. is a consultant to and holds equity in Catalio Capital Management. S.Z. has a research agreement with BioMed Valley Discoveries. C.B. is a consultant to Depuy-Synthes, Bionaut Labs, Haystack Oncology,\u00a0Privo Technologies and Galectin Therapeutics; a co-founder of OrisDx; and a co-founder of Belay Diagnostics. D.M.P. reports grant and patent royalties through institution from BMS, a grant from Compugen, stock from Trieza Therapeutics and Dracen Pharmaceuticals and founder equity from Potenza; being a consultant for Aduro Biotech, Amgen, Astra Zeneca (Medimmune\/Amplimmune), Bayer, DNAtrix, Dynavax Technologies Corporation, Ervaxx, FLX Bio, Rock Springs Capital, Janssen, Merck, Tizona and Immunomic Therapeutics; being on the scientific advisory board of Five Prime Therapeutics, Camden Nexus II, WindMil; and being on the board of directors for Dracen Pharmaceuticals. The companies named above, as well as other companies, have licensed previously described technologies related to the work described in this paper from Johns Hopkins University. B.V., K.W.K. and N.P. are listed as inventors of some of these technologies. Licences to these technologies are or will be associated with equity or royalty payments to the inventors as well as to Johns Hopkins University. Patent applications on the work described in this paper may be filed by Johns Hopkins University. The terms of all of these arrangements are being managed by Johns Hopkins University according to its conflict of interest policies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}